Callerio Foundation

Updating of published results (page 2)

Bouma M, Nuijen B, Jansen MT, Sava G, Bult A, Beijnen JH.
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
J Pharm Biomed Anal, 30: 1287-1296, 2002. Abstract

Bouma M, Nuijen B, Sava G, Perbellini A, Flaibani A, van Steenbergen MJ, Talsma H, Ketten-van den Bosch JJ, Bult A, Beijnen JH.
Pharmaceutical development of a parental lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Int J Pharm, 248: 247-259, 2002. Abstract

Bouma M, Nuijen B, Jansen MT, Sava G, Flaibani A, Bult A, Beijnen JH.
A kinetic study of the chimica stability of the antimetastatic ruthenium complex NAMI-A.
Int J Pharm, 248: 239-246, 2002. Abstract

Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, Sava G, Ventura C.
The antimetastatic agent imidazolium trans-imidazoletetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signalling pathway.
Arch Biochem Biophys, 403: 209-218, 2002. Abstract (PDF)

Pacor S, Giangaspero A, Bacac M, Sava G, Tossi A.
Analysis of cytotoxicity of synthetic antimicrobial peptides on mouse leukocytes: implications for systemic use.
J Antimicrob Chemother, 50: 339-348, 2002. Abstract

Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A, Garbisa S, Sartor L, Sava G.
Inhibition of endothelial cell functions and angiogenesis by the metastasis inhibitor NAMI-A.
Brit J Cancer, 86: 993-998, 2002. Abstract

Cocchietto M, Skert N, Nimis PL and Sava G.
A review on usnic acid, an interesting natural compound.
Naturwissenshaften 89: 137-146, 2002. Abstract

Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, Scarcia A, Serli B, Iengo E, Alessio E and Mestroni G.
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
European Journal of Cancer, 38: 427-435, 2002. Abstract

Pacor S, Vadori M, Vita F, Bacac M, Soranzo MR, Zarucchi G, Sava G.
Isolation of a murine metastatic cell line and preliminary sensitività to the antimetastasis agent NAMI-A.
Anticancer Res, 21: 2523-2530, 2001. Abstract

Bergamo A, Zorzet S, Cocchietto M, Carotenuto ME, Magnarin M, Sava G.
Tumour cell uptake, G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Anticancer Res, 21: 1893-1898, 2001. Abstract

Crul M, van den Bongard HJGD, Tibben MM, van Tellingen O, Sava G, Schellens JHM, Beijinen JH.
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectroscopy.
Fresenius J Anal Chem, 369: 442-445, 2001. Abstract

Pacor S, Bacac M, Vadori M, Vismara D, Manfrin A, Sava G.
Immunostimulating effects of oral lysozyme on a vaccination treatment with Vibrio anguillarum.
Far Ter, XVIII: 51-55, 2001. Abstract (PDF)

Zorzet S, Sorc A, Casarsa C, Cocchietto M, Sava G.
Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma.
Metal Based Drugs, 8: 1-7, 2001. Abstract

Bergamo A, Zorzet S, Gava B, Sorc A, Alessio E, Iengo E, Sava G.
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Anti-Cancer Drugs, 11: 667-672, 2000. Abstract

Sava G, Cocchietto M.
Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy Beagle dogs.
In Vivo, 14: 741-744, 2000. Abstract

Cocchietto M, Sava G.
Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.
Pharmacol Toxicol, 87: 193-197, 2000 Abstract

Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E, Iengo E, Sava G.
Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo selective antimetastasis activity of ruthenium complexes.
J Pharmacol Expl Ther, 295: 927-933, 2000. Abstract

Alessio E, Iengo E, Zorzet S, Bergamo A, Coluccia M, Boccarelli A, Sava G.
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[(trans-RuCl4(Me2SO)]2(mu-L)] (L= ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
J Inorg Biochem, 79: 173-177, 2000. Abstract

Magnarin M, Bergamo A, Carotenuto ME, Zorzet S, Sava G.
Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Anticancer Res, 20: 2939-2944, 2000. Abstract

Sava G, Bergamo A.
Ruthenium-based compounds and tumour growth control (Review).
Int J Oncol, 17: 353-365, 2000. Abstract

Cocchietto M, Salerno G, Alessio E, Mestroni G, Sava G.
Fate of the antimetastatic ruthenium complex ImH[trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Anticancer Res, 20: 197-202, 2000. Abstract

Pacor S, Magnarin M, Carotenuto ME, Spessotto P, Zabucchi G, Sava G.
In vitro growth of TS/A adenocarcinoma and of the gene transfected TS/A-IL4 line on biological substrates.
Anticancer Res, 20: 191-196, 2000. Abstract

Callerio C, Gagliardi R, Sava G.
Amplificazione della replicazione batteriofagica con batteri in fase stazionaria.
Boll Soc Adr Sci, LXXVIII: 35-38, 1999. Abstract (PDF)

Pacor S, Gagliardi R, Di Daniel E, Vadori M, Sava G.
In vitro down regulation of ICAM-1 and E-cadherin and in vivo reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative.
Int J Mol Med, 4: 369-375, 1999. Abstract

Pacor S, Gagliardi R, Spessotto P, Zabucchi G, Sava G.
Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth.
Pathol Oncol Res, 5: 110-116, 1999. Abstract

Sava G, Alessio E, Bergamo A, Mestroni G.
Sulphoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumour metastases.
In: Topics in Biological Inorganic Chemistry – Metallopharmaceuticals I. (MJ Clarke, PJ Sadler Eds.), pp.143-169, Springer, Berlin, 1999. Abstract (PDF)

Sava G, Bergamo A.
Drug control of solid tumour metastases: a critical view.
Anticancer Res., 19: 1117-1124, 1999. Abstract

Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G.
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
Anticancer Res., 19: 969-972, 1999. Abstract

Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G.
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
J. Pharmacol. Expl. Ther., 289: 559-564, 1999. Abstract

Sava G, Clerici K, Capozzi I, Cocchietto M, Gagliardi R, Alessio E, Mestroni G, Perbellini A.
Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Anti Cancer Drugs, 10: 129-138, 1999 Abstract

Pacor S, Gagliardi R, Magnarin M, Carotenuto ME, Zabucchi G, Sava G.
Reduction of growth ability and tumorigenicity of IL-4 transfected TS/A adenocarcinoma line is mediated by increased adhesion molecule expression.
Haematologica, 83 (meeting supplement): 22-23, 1998. Abstract (PDF)

Sava G, Gagliardi R, Cocchietto M, Clerici K, Capozzi I, Marrella M, Alessio E, Mestroni G, Milanino R.
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
Pathol Oncol Res, 4: 30-36, 1998. Abstract

Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G.
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Clin Exp Metastasis, 16: 371-379, 1998. Abstract

Capozzi I, Clerici K, Cocchietto M, Salerno G, Bergamo A, Sava G.
Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
Chem-Biol Interactions, 113: 51-64, 1998. Abstract

Sava G, Gagliardi R, Pacor S.
Modulation of host immunity by lysozymes active on GALT in mice carrying solid malignant tumours.
Curr Topics Pharmacol, 3: 239-245, 1997. Abstract (PDF)

Alessio E, Mestroni G, Sava G, Bergamo A, Coluccia M, Messori L.
Ruthenium-sulphoxide complexes with a specific antimetastatic activity.
In: Cytotoxic, mutagenic and Carcinogenic Potential of Heavy Metals Related to human Environment. (ND Hadjiliadis Ed.), pp. 457-466, Kluwer Academic Publishers, Boston, 1997. Abstract (PDF)

Sava G, Bergamo A.
Pharmacological control of solid tumour metastases by ruthenium complexes.
Curr Topics Pharmacol, 3: 207-216, 1997. Abstract

Bergamo A, Cocchietto M, Capozzi I, Mestroni G, Alessio E, Sava G.
Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im] and ruthenium uptake by tumor cells.
Anti-Cancer Drugs, 7: 1-6, 1996. Abstract

Sava G, Bergamo A, Capozzi I, Clerici K, Pacor S, Gagliardi R, Giacomello E, Zacchigna M, Di Luca G, Boccù E.
Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma.
J. Exp. Ther. Oncol., 1: 15-23, 1996. Abstract

Rosati A, Clerici K, Bergamo A, Sava G.
Identification and measurement of transferrin receptors in a T-cell lymphocyte population by a fluorescent ligand.
Cell Pharmacol, 3: 225-230, 1996. Abstract (PDF)

Pacor S, Giacomello E, Bergamo A, Clerici K, Zacchigna M, Boccù E, Sava G.
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma.
Anticancer Res, 16: 2559-2564, 1996. Abstract

Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S.
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex.
Int J Cancer, 68: 60-66, 1996. Abstract

Cartei G, Sava G, Salerno G, Bergamo A, Cartei F, Sanzari M, Sala PG, Vigevani E, Tabaro G, Clocchiatti L.
Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients.
Cancer Biother and Radiopharm, 11: 105-111, 1996. Abstract

Sava G.
Pharmacological aspects and therapeutic applications of lysozymes.
In: Lysozymes: Model Enzymes in Biochemistry and Biology (Jollès P, ed.), pp. 433-449, Birkhäuser Verlag, Basel, 1996. Abstract

Cocchietto M, Salerno G, Mestroni E, Alessio E, Sava G.
Determination of ruthenium by atomic absorption spectroscopy after treatment with Na[trans-RuCl4(DMSO)Im].
In: Metal Ions in Biology and Medicine (Collery P, Corbella J, Domingo JL, Etienne JC, Llobet JM, eds.) vol. 4, pp. 381-383, John Libbey Eurotext, Paris, 1996. Abstract (PDF)

Sava G, Salerno G, Bergamo A, Cocchietto M, Gagliardi R, Alessio E, Mestroni G.
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization.
Metal Based Drugs, 3: 67-73, 1996. Abstract

Sava G, Pacor S, Dasic G, Bergamo A.
Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas.
Anticancer Res, 15: 1883-1888, 1995. Abstract

Pacor S, Giacomello E, Bergamo A, Gagliardi R, Cocchietto M, Sava G.
Cytofluorimetric analysis of gut-intraepitelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme.
Anticancer Res. 16: 145-150, 1996. Abstract

Coluccia M, Sava G, Salerno G, Bergamo A, Pacor S, Mestroni G, Alessio E.
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma.
Metal Based Drugs, 2: 195-199, 1995. Abstract

Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E.
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition.
Chem-Biol Interact, 95: 109-126, 1995. Abstract

Sava G, Pacor S, Coluccia M, Mariggiò M, Cocchietto M, Alessio E, Mestroni G.
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex.
Drug Invest, 8: 150-161, 1994. Abstract (PDF)

Dasic G, Pacor S, Bergamo A, Salerno G, Vranesic B, Jukic R, Tomasic J, Sava G.
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse.
Int J Oncology, 5: 275-284, 1994. Abstract

Gagliardi R, Sava G, Pacor S, Mestroni G, Alessio E.
Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
Clin Exp Metastasis, 12: 93-100, 1994. Abstract

Pacor S, Franz C, Gagliardi R, Sava G.
Lysozyme induced recovery of the responce to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma.
Int J Oncology, 4: 877-883, 1994. Abstract

Cartei G, Sava S, Salerno G, Sala PG, Vigevani E, Ceschia V, Clocchiatti L, Tabaro G.
Synthetic thymic fraction 5: 24 hours high dose administration and circulating lymphocytes in immunodepressed patients.
Preliminary results. In: “Advances in management of malignancies” (A Carpi, A Sagripanti, B Grassi Eds.), pp 245-246, Editoriale Bios s.s.s., Pisa, Italy, 1993. Abstract

Sava G, Pacor S, Alessio E, Mestroni G, Gagliardi R, Cocchietto M, Coluccia M.
Drugs of the Future, 18: 894-900, 1993 Abstract (PDF)

G. Sava, S. Pacor, B. Vranesic, J. Tomasic, M. Cocchietto.
Modification of the growth of MCa Mammary carcinoma of CBA mouse by new adamantylpeptides.
International Journal of Oncology 2: 607-612, 1993. Abstract

G. Sava, S. Pacor, E. Nardon, A. Dobrina.
Effects of Endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride.
Journal of Chemotherapy 4: 228-234, 1992. Abstract

G. Sava, S. Pacor, G. Mestroni, E. Alessio.
Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im] and [trans-RuCl4(DMSO)Im]Na on solid mouse tumors.
Anti-cancer Drugs, 3: 25-31, 1992. Abstract

S. Pacor, G. Sava, G. Mestroni, E. Alessio.
Tumor inhibition and effects on host survival time by rutheniumIII and rhodiumIII complexes with dimethylsulphoxide ligands.
Pharmacol Res, 25: 73-74, 1992. Abstract

S. Pacor, G. Sava, V. Ceschia, F. Bregant, G. Mestroni, E. Alessio.
Antineoplastic effects of mer-trichlorobisdimethylsulphoxideaminoruthenium(III) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]
Chem Biol Interactions 78: 223-234, 1991. Abstract

Updating of published results (page 1)


Plain language articles